

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

16768  
F1

In re Patent Application of

Atty Dkt. 1579-628  
C# M#

HALE et al

TC/A.U. 1642

Serial No. 09/998,923

Examiner: Ungar, S.

Filed: December 3, 2001

Date: January 27, 2005

Title: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.

## Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$50.00	\$0.00 (1202)/\$0.00 (2202) \$
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$200.00	\$0.00 (1201)/\$0.00 (2201) \$

If proper multiple dependent claims now added for first time, (ignore improper); add  
\$360.00 (1051)/\$180.00 (2051) \$

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s)

One Month Extension	\$120.00 (1251)/\$60.00 (2251)
Two Month Extensions	\$450.00 (1252)/\$225.00 (2252)
Three Month Extensions	\$1020.00 (1253)/\$510.00 (2253)
Four Month Extensions	\$1590.00 (1254)/\$795.00 (2254) \$

Terminal disclaimer enclosed, add  
\$130.00 (1814)/ \$65.00 (2814) \$

Applicant claims "small entity" status.  Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee	\$180.00 (1806)	\$ 180.00
---	-----------------	-----------

Assignment Recording Fee	\$40.00 (8021)	\$
--------------------------	----------------	----

Other:		\$
--------	--	----

**TOTAL FEE ENCLOSED \$ 180.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
MJW:tat

NIXON & VANDERHYE P.C.  
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HALE et al

Serial No. 09/998,923

Filed: December 3, 2001

For: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF  
CANCER



Confirmation No. 4251

Atty. Ref.: 1579-628

Group: 1642

Examiner: Ungar, S.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**January 27, 2005**

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C

2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00

3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each  
identified document and a translation or a concise explanation of  
each non-English language document (such as a Search Report) is  
enclosed herewith.

01/31/2005 HGUTERAI 00000114 09998923  
01 FC:1806

180.00 0P

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
  - a) The required Statement made in item 8 below; or
  - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
  - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
  - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
  - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: Mary J. Wilson  
Mary J. Wilson  
Reg. No. 32,955

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

## **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

**Atty. Docket No.**

**1579-628**

**Applicant**

HALE et al

**Filing Date**

**December 3, 2001**

**Serial No.**

09/998,923



TC/A.U.

1642

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## TRANSLATION

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

Agarwal et al, "Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-release hormone analogue in prostate cancer and benign prostatic hyperplasia", BJU International 85:690-695 (2000)

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.